Abstract:The low oral bioavailability of clozapine due to its poor aqueous solubility, poor dissolution rate, and extensive hepatic first-pass metabolism poses a challenge to the effective treatment of psychiatric disorders. The objective of the current research was to address the above issues by developing a clozapine inclusion complex (CLZ-IC) using the microwave irradiation method. To optimize the formulation and processing variables, namely the molar ratio of CLZ to β-CD (X 1 ) and the irritation reaction time (X 2 ), a 3 2 factorial design was performed. The phase solubility study revealed the formation of a stable inclusion complex with a stoichiometry of 1:1, suggesting that β-cyclodextrin could effectively solubilize clozapine. The characterization data confirmed the formation of the inclusion complex of clozapine in β-cyclodextrin. The optimized inclusion complex showed a solubility of 342 ± 26 μg/ml and a percentage dissolution of 91.1 ± 3.4% after four hours. The inclusion-complex tablets exhibited excellent physical properties and showed an improved in vitro dissolution profile, with 80% of the drug being released within 100 minutes, compared to marketed tablets (80% release in 300 min). In vivo pharmacokinetic studies conducted in a rat model demonstrated an increase in C max , area under the curve (AUC), and relative bioavailability by a factor of 2.26 with the optimized formulation, indicating a significant improvement in drug absorption compared to the marketed tablet. The techno-economic analysis suggests a cost-benefit ratio of 25.08 after 7 years, indicating the suitability for large-scale production. Overall, using Design of Experiment, in silico, and in vivo studies proved effective in optimizing the inclusion-complex formation and enhancing the bioavailability of clozapine. In conclusion, the optimized clozapine-β-cyclodextrin inclusion complex prepared using a time-saving (90 sec) and cost-effective microwave irradiation method exhibited excellent physical properties and demonstrated significant improvements in the drug's solubility, dissolution rate, and pharmacokinetic performance.

Formulation and in Vivo Evaluation of Orally Disintegrating Tablets of Clozapine/Hydroxypropyl-β-cyclodextrin Inclusion Complexes

Enhancing the Bioavailability of Clozapine through Microwave-Assisted Formulation of a Stable β-Cyclodextrin Inclusion Complex

Development of Orally Disintegrating Tablets of Perphenazine/hydroxypropyl-β-cyclodextrin Inclusion Complex

Formulation and statistical optimization of clozapine solid self emulsification system for improving the dissolution properties

Development and Evaluation of an Orodispersible Tablet Formation for the Delivery of a Hydrophobic Drug

Preparation, Physicochemical Characterization and in Vitro Dissolution Studies of Azithromycin-Cyclodextrin Inclusion Complexes

Investigation the complex of 2,6-di-O-methyl-β-cyclodextrin and chlorzoxazone: preparation, characterization, dissolution, and cytotoxicity

Inclusion complexes of chlorzoxazone with β- and hydroxypropyl-β-cyclodextrin: Characterization, dissolution, and cytotoxicity

The hydroxypropyl-β-cyclodextrin complexation of toltrazuril for enhancing bioavailability.

Characterization And In Vivo Evaluation Of An Inclusion Complex Of Oridonin And 2-Hydroxypropyl-Beta-Cyclodextrin

Improving Lurasidone Hydrochloride's Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin

Characterization and In Vitro Evaluation of the Complexes of Posaconazole with β- and 2,6-di-O-methyl-β-cyclodextrin

Formulation, Development, and in-vitro Evaluation of Escitalopram Fast Dissolving Tablets

Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-β-cyclodextrin complex

Preparation,Characterization,Muscular Stimulation and Pharmacokinetics of the Inclusion Complex of Iloperidone-Hydroxypropyl-β-Cyclodextrin

Enhanced Dissolution and Stability of Lansoprazole by Cyclodextrin Inclusion Complexation: Preparation, Characterization, and Molecular Modeling

Formulation and Characterization of a Ternary Inclusion Complex Containing Hydroxypropyl-β-cyclodextrin and Meglumine for Solubility Enhancement of Poorly Water-Soluble ST-246, an Anti-Smallpox Drug.

Design, Optimization and Evaluation of Lurasidone Hydrochloride Nanocrystals as Fast Disintegrating Tablets

Preparation, characterization and pharmacokinetic studies of sulfobutyl ether-β-cyclodextrin-toltrazuril inclusion complex

Formulation and characterization of oral rapid disintegrating tablets of levocetirizine

Development of Metformin Hydrochloride Loaded Dissolving Tablets with Novel Carboxymethylcellulose/poly-L-lysine/tpp Complex